LungLife AI

About:

LungLife AI is a molecular diagnostics company that involves in the early detection and treatment of cancer.

Website: https://www.lunglifeai.com

Twitter/X: LungLifeAI

Top Investors: Greenwoods Asset Management, Syno Capital, Livzon Pharmaceutical Group

Description:

LungLife AI is a molecular diagnostics company that involves in the early detection and treatment of cancer. It uses machine learning and artificial intelligence to enable life-saving early diagnosis of lung cancer. The company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled the molecular analysis of cancer biomarkers in blood. The company is developing tests that span all stages of lung cancer from aid in diagnosis for patients with early-stage disease to treatment stratification and monitoring in late-stage lung cancer. The company's diagnostic technology combined with machine learning and image analysis results in workflow efficiencies and improvement in performance. It was founded in 2008 and is headquartered in Thousand Oaks, California.

Total Funding Amount:

$56.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Thousand Oaks, California, United States

Founded Date:

2006-01-01

Founders:

Alan J. Heeger, Fred Gluck

Number of Employees:

11-50

Last Funding Date:

2024-03-22

IPO Status:

Public

© 2024 MyAiNote.com